2024 Prediction from Greg Baker
Greg Baker is the CEO of AffirmedRx. He predicts that "transparent PBMs will gain traction" in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Greg Baker said:
“In 2024, Optum Rx will follow suit with their own group purchasing organization (GPO) spinoff so they can take advantage of acquisition price models like CVS’ Averon and Express Scripts’
ClearNetwork. Several media outlets have compared these programs to the Mark Cuban Cost Plus Drug Company, but unlike Cost Plus, which fully discloses what it pays for medications, none of these GPOs will take a similar stance on disclosure.
Transparent PBMs will continue to gain traction in the market as traditional PBMs continue to lead employers to higher-cost, opaque models. Employers are told each year that their drug discounts will get better and their rebates will improve and yet every year their overall costs continue to increase.
Plan sponsors pharmaceutical costs will increase in 2024 and profits associated with companies that own traditional PBMs will see profit increases across all of their affiliate organizations.”
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 31st 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
First-in-Class Therapy for Diabetic Retinopathy Shows Six-Month Benefit | ASRS 2025
July 31st 2025PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block endothelin signaling to increase ocular blood flow and prevent vision loss.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
July 31st 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
